Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Recruiting now · Phase 1

Conditions studied: Neoplasms

In brief

This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

Key facts

Study ID

NCT03391778

Run by

USWM CT, LLC

People needed

250

Starts

2018-04-09

Expected to finish

2032-04-01

Last updated by the study team

2026-03-03

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants who have received at least one dose of ADP adoptive cell therapy agent.
• Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it.
• Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy.
• Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
• The investigator is responsible for review of medical history.
• Capable of giving signed informed consent.

You may not qualify if…

• None

Where it is running

• The Royal Marsden NHS Foundation Trust — Sutton, United Kingdom (enrolling)
• ADP Investigational Site — Baltimore, Maryland, United States (enrolling)
• Emory University School of Medicine — Atlanta, Georgia, United States (enrolling)
• University of Michigan — Ann Arbor, Michigan, United States (enrolling)
• Washington University School of Medicine in St. Louis — St Louis, Missouri, United States (enrolling)
• Memorial Sloan Kettering Cancer Center - New York — New York, New York, United States (enrolling)
• Duke University Medical Center — Durham, North Carolina, United States (enrolling)
• Oregon Health and Science University — Portland, Oregon, United States (enrolling)
• University of Pennsylvania — Philadelphia, Pennsylvania, United States (enrolling)
• University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center — Pittsburgh, Pennsylvania, United States (enrolling)
• University of Texas Southwestern Medical Center — Dallas, Texas, United States (enrolling)
• University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
• Froedtert Hospital — Milwaukee, Wisconsin, United States (enrolling)
• Peter MacCallum Cancer Centre — Melbourne, Victoria, Australia (enrolling)
• Princess Margaret Cancer Centre — Toronto, Ontario, Canada (enrolling)
• Hôpital Maisonneuve-Rosemont — Montreal, Quebec, Canada (enrolling)
• Klinikum rechts der Isar der Technischen Universität München — Munich, Bavaria, Germany (enrolling)
• Uniklinik Köln — Cologne, North Rhine-Westphalia, Germany (enrolling)
• Fondazione IRCCS - Istituto Nazionale dei Tumori — Milan, Lombardy, Italy (enrolling)
• Antoni Van Leeuwenhoek Ziekenhuis — Amsterdam, Netherlands (enrolling)
• Hospital Universitario Virgen del Rocío — Seville, Spain (enrolling)
• University College London Hospitals NHS Foundation Trust — London, United Kingdom (enrolling)
• USWM CT Investigational Site — Manchester, United Kingdom (enrolling)
• National Cancer Institute - Center for Cancer Research — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.